아스피린을 복용하던 급성 뇌경색 환자에서 생화학적 아스피린저항성이 뇌경색의 중증도에 미치는 영향
Biochemical Aspirin Resistance Affect on Stroke Severity in Acute Stroke Patients Who Had Taken Aspirin
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: There are conflicting data in the literature regarding aspirin resistance. This study evaluated the effect of biochemical aspirin resistance on initial stroke severity in acute stroke patients who had taken aspirin. Methods: We reviewed acute ischemic stroke patients who were already on aspirin. Biochemical aspirin resistance was defined as an aspirin reaction unit score of ≥550, as evidenced by the VerifyNow-Aspirin assay, which was performed after 4 days of continuous aspirin medication. Initial stroke severity was evaluated using National Institutes of Health Stroke Scale (NIHSS) scores at day 4, which were dichotomized into mild (0-7) and severe (≥8). Modified Rankin Scale scores were determined at 3 months. The Alberta Stroke Program Early CT Scores (ASPECTS) were assessed on initial diffusion-weighted imaging (DWI). We examined the relationships between biochemical aspirin resistance and initial stroke severity. Results: Nine of 106 patients (8.5%) had biochemical aspirin resistance. The initial stroke severity was significantly associated with DWI-ASPECTS (p<0.001), initial C-reactive protein level (p=0.005), biochemical aspirin resistance (p=0.009), and stenosis or occlusion of the relevant artery (p=0.029). Multivariate analysis showed that biochemical aspirin resistance [odds ratio (OR), 15.24; 95% confidence interval (CI), 2.49-93.31; p=0.003] and initial C-reactive protein level (per 1 mg/dL; OR, 2.43; 95% CI, 1.47-4.00; p=0.001) were independently associated with initial stroke severity (NIHSS score ≥8). However, biochemical aspirin resistance was not associated with clinical outcome at 3 months (p=0.366). Conclusions: Biochemical aspirin resistance was independently associated with initial stroke severity. This suggests that detection of biochemical aspirin resistance in acute ischemic stroke is useful when choosing the optimal treatment. J Korean Neurol Assoc 29(4):303-308, 2011
Abstract
Background: There are conflicting data in the literature regarding aspirin resistance. This study evaluated the effect of biochemical aspirin resistance on initial stroke severity in acute stroke patients who had taken aspirin. Methods: We reviewed acute ischemic stroke patients who were already on aspirin. Biochemical aspirin resistance was defined as an aspirin reaction unit score of ≥550, as evidenced by the VerifyNow-Aspirin assay, which was performed after 4 days of continuous aspirin medication. Initial stroke severity was evaluated using National Institutes of Health Stroke Scale (NIHSS) scores at day 4, which were dichotomized into mild (0-7) and severe (≥8). Modified Rankin Scale scores were determined at 3 months. The Alberta Stroke Program Early CT Scores (ASPECTS) were assessed on initial diffusion-weighted imaging (DWI). We examined the relationships between biochemical aspirin resistance and initial stroke severity. Results: Nine of 106 patients (8.5%) had biochemical aspirin resistance. The initial stroke severity was significantly associated with DWI-ASPECTS (p<0.001), initial C-reactive protein level (p=0.005), biochemical aspirin resistance (p=0.009), and stenosis or occlusion of the relevant artery (p=0.029). Multivariate analysis showed that biochemical aspirin resistance [odds ratio (OR), 15.24; 95% confidence interval (CI), 2.49-93.31; p=0.003] and initial C-reactive protein level (per 1 mg/dL; OR, 2.43; 95% CI, 1.47-4.00; p=0.001) were independently associated with initial stroke severity (NIHSS score ≥8). However, biochemical aspirin resistance was not associated with clinical outcome at 3 months (p=0.366). Conclusions: Biochemical aspirin resistance was independently associated with initial stroke severity. This suggests that detection of biochemical aspirin resistance in acute ischemic stroke is useful when choosing the optimal treatment. J Korean Neurol Assoc 29(4):303-308, 2011
참고문헌 (26)
- Gum PA, "Profile and prevalence of aspirin resistance in patients with cardiovascular disease", Am J Cardiol, 88, pp.230~235 (2001)
- Eikelboom JW, "Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events", Circulation, 105, pp.1650~1655 (2002)
- "Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients", BMJ, 324, pp.71~86 (2002)
- Howard PA, "Aspirin resistance", Ann Pharmacother, 36, pp.1620~1624 (2002)
- "Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators", JAMA, 279, pp.1265~1272 (1998)
- Alberts MJ, "Antiplatelet effect of aspirin in patients with cerebrovascular disease", Stroke, 35, pp.175~178 (2004)
- Helgason CM, "Aspirin response and failure in cerebral infarction", Stroke, 24, pp.345~350 (1993)
- Grotemeyer KH, "Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients", Thromb Res, 71, pp.397~403 (1993)
- Grundmann K, "Aspirin non-responder status in patients with recurrent cerebral ischemic attacks", J Neurol, 250, pp.63~66 (2003)
- Gum PA, "A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease", J Am Coll Cardiol, 41, pp.961~965 (2003)
- Mirkhel A, "Frequency of aspirin resistance in a community hospital", Am J Cardiol, 98, pp.577~579 (2006)
- Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment", Stroke, 24, pp.35~41 (1993)
- Berrouschot J, "Aspirin resistance in secondary stroke prevention", Acta Neurol Scand, 113, pp.31~35 (2006)
- 김태형, "신속혈소판기능검사를 이용한 허혈성 뇌졸중 환자에서 아스피린 저항성의 빈도와 관련인자 - 예비연구", 대한뇌졸중학회지, 8(1), pp.80~85 (2006), 대한뇌졸중학회
- Lee JH, "Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial", EUROPEAN JOURNAL OF NEUROLOGY, 17(3), pp.434~442 (2010), WILEY-BLACKWELL PUBLISHING
- Davalos A, "The clinical-DWI mismatch: a new diagnostic approach to the brain tissue at risk of infarction", Neurology, 62, pp.2187~2192 (2004)
- Singer OC, "Risk assessment of symptomatic intracerebral hemorrhage after thrombolysis using DWI-ASPECTS", Stroke, 40, pp.2743~2748 (2009)
- Barber PA, "Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score", Lancet, 355, pp.1670~1674 (2000)
- Seok JI, "Can aspirin resistance be clinically predicted in stroke patients", Clin Neurol Neurosurg, 110, pp.110~116 (2008)
- Varanasi JS, "Antiplatelet effect of aspirin in patients with cerebrovascular disease", Stroke, 35, pp.144~145 (2004)
- 방오영, "뇌졸중 환자에게 아스피린과 클로피도그렐 내성", 대한뇌졸중학회지, 11(1), pp.1~9 (2009), 대한뇌졸중학회
- Englyst NA, "Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity", J Cereb Blood Flow Metab, 28, pp.1196~1203 (2008)
- 전성만, "급성기 뇌경색에서의 Clopidogrel의 저항성", 대한신경과학회지, 24(4), pp.319~323 (2006), 대한신경과학회
- Aydinalp A, "The clinical significance of aspirin resistance in patients with chest pain", Clin Cardiol, 33, pp.1~7 (2010)
- Bamford J, "Classification and natural history of clinically identifiable subtypes of cerebral infarction", Lancet, 337, pp.1521~1526 (1991)
- Hankey GJ, "Aspirin resistance", BMJ, 328, pp.477~479 (2004)